News Archive

The content below is specific to Novartis Canada. To see all Novartis content, please visit the Novartis Global site.

2022

October

Media Release / Oct 14, 2022

Gene therapy Luxturna® now reimbursed in Quebec for people with previously untreatable inherited vision loss¹

Read More

September

Media Release / Sep 21, 2022

Novartis and the pan-Canadian Pharmaceutical Alliance (pCPA) conclude negotiations for Luxturna®, a gene therapy for previously untreatable inherited vision loss¹

Read More
Media Release / Sep 07, 2022

Health Canada approves PLUVICTO™ as first targeted radioligand therapy for progressive PSMA positive metastatic castration-resistant prostate cancer

Read More

August

Media Release / Aug 31, 2022

Scemblix™, a first-in-class CML treatment with new mechanism of action approved in Canada

Read More

June

Media Release / Jun 09, 2022

Novartis Pro Portal reimagines knowledge exchange in patient care, with seamless collaboration between the pharmaceutical industry and physicians

Read More
Media Release / Jun 09, 2022

Health Canada approves PrTabrecta®: Targeted cancer therapy for locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations

Read More

April

Media Release / Apr 25, 2022

Ontario and Quebec become the first provinces to list Kesimpta® (ofatumumab) for the treatment of adults with relapsing remitting multiple sclerosis (RRMS)

Read More
2021

December

Media Release / Dec 17, 2021

Beovu® (brolucizumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of neovascular (wet) age-related macular degeneration

Read More

October

Media Release / Oct 27, 2021

Novartis launches Not Another Minute to educate Canadians and take action to bend the curve of cardiovascular disease (CVD)

Read More
Media Release / Oct 19, 2021

Novartis applauds Quebec, the first province to list Zolgensma® for the treatment of pediatric patients with spinal muscular atrophy (SMA)

Read More